Abstract Background Lenvatinib is a tyrosine kinase inhibitor with novel binding ability. It is considered the standard of care for metastatic thyroid cancer; moreover, whether it is indicated for other malignant tumors has been examined. Lenvatinib increases the risk of kidney injury in some patients. In comparison with sorafenib, which is a conventional tyrosine kinase inhibitor (TKI), lenvatinib results in more side effects, including hypertension and proteinuria. We describe a case of secondary focal segmental glomerulosclerosis (FSGS) that developed following treatment of metastatic thyroid cancer with lenvatinib and reviewed the mechanisms of renal impairment. Case presentation We describe a patient with metastatic thyroid cancer who ...
Abstract Background Glomerular endotheliosis is the pathognomonic glomerular lesion in pre-eclampsia...
INTRODUCTION: Immune checkpoint inhibitors have taken an important place in the treatment of differe...
A patient with advanced gastrointestinal stromal tumor (GIST) receiving second-line treatment with s...
We describe a case of lenvatinib (E7080) associated focal segmental glomerulosclerosis (FSGS) encoun...
We describe a case of lenvatinib (E7080) associated focal segmental glomerulosclerosis (FSGS) encoun...
We describe a case of lenvatinib (E7080) associated focal segmental glomerulosclerosis (FSGS) encoun...
Introduction: Lenvatinib (LEN) is a multi-kinase anti-angiogenic drug recently approved in several c...
Standard therapy for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) is mult...
Abstract Background Because lenvatinib is well known to induce proteinuria by blocking the vascular ...
Antiangiogenic therapy targeting vascular endothelial growth factor (VEGF) or its receptor (VEGFR) h...
BACKGROUND: Drugs targeting the VEGF pathway are associated with renal adverse events, including pro...
A male patient in his 70s with hepatocellular carcinoma(HCC)was treated using sorafenib, but treatme...
Abstract Background There are ...
Lenvatinib is a small oral molecule able to inhibit three of the extracellular and intracellular mol...
Purpose: The use of tyrosine kinase inhibitors (TKIs) in thyroid cancer patients is often limited by...
Abstract Background Glomerular endotheliosis is the pathognomonic glomerular lesion in pre-eclampsia...
INTRODUCTION: Immune checkpoint inhibitors have taken an important place in the treatment of differe...
A patient with advanced gastrointestinal stromal tumor (GIST) receiving second-line treatment with s...
We describe a case of lenvatinib (E7080) associated focal segmental glomerulosclerosis (FSGS) encoun...
We describe a case of lenvatinib (E7080) associated focal segmental glomerulosclerosis (FSGS) encoun...
We describe a case of lenvatinib (E7080) associated focal segmental glomerulosclerosis (FSGS) encoun...
Introduction: Lenvatinib (LEN) is a multi-kinase anti-angiogenic drug recently approved in several c...
Standard therapy for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) is mult...
Abstract Background Because lenvatinib is well known to induce proteinuria by blocking the vascular ...
Antiangiogenic therapy targeting vascular endothelial growth factor (VEGF) or its receptor (VEGFR) h...
BACKGROUND: Drugs targeting the VEGF pathway are associated with renal adverse events, including pro...
A male patient in his 70s with hepatocellular carcinoma(HCC)was treated using sorafenib, but treatme...
Abstract Background There are ...
Lenvatinib is a small oral molecule able to inhibit three of the extracellular and intracellular mol...
Purpose: The use of tyrosine kinase inhibitors (TKIs) in thyroid cancer patients is often limited by...
Abstract Background Glomerular endotheliosis is the pathognomonic glomerular lesion in pre-eclampsia...
INTRODUCTION: Immune checkpoint inhibitors have taken an important place in the treatment of differe...
A patient with advanced gastrointestinal stromal tumor (GIST) receiving second-line treatment with s...